|
For other uses, see Bayer (disambiguation). Bayer AG (German pronunciation "BYE-er", in US usually pronounced "BAY-er") (, ) is a German chemical and pharmaceutical company founded in 1863. It is headquartered in Leverkusen, North Rhine-Westphalia, Germany. It is well-known for its original brand of aspirin.
About Bayer AG In order to separate operational and strategic management Bayer AG was reorganized into a holding company in December 2003. The group's core businesses were transformed into limited companies, each controlled by Bayer AG. These companies are: Bayer CropScience AG; Bayer HealthCare AG; Bayer Material Science AG and Bayer Chemicals AG and the three service companies Bayer Technology Services GmbH, Bayer Business Services GmbH and Bayer Industry Services GmbH & Co. OHG. Following Bayer's successful reorganization, its chemicals activities (with the exception of H.C. Starck and Wolff Walsrode) have been combined with certain components of the polymers segment to form the new company LANXESS. This change took place on July 1, 2004, with LANXESS to be listed on the stock exchange by the beginning of 2005. Bayer AG shares are listed on the Frankfurt Stock Exchange, the London Stock Exchange and on the New York Stock Exchange. Bayer is governed by a board of management, consisting of: Klaus Kühn, Udo Oels, Richard Pott, and Werner Wenning. In 2004 Bayer Healthcare AG acquired the OTC Pharmaceutical Division of Roche Pharmaceuticals. On March 13, 2006, Merck KGaA announced a €14.6bn bid for Schering. The offer document is due to be issued in early April 2006. Merck's takeover bid was surpassed by Bayer's $19.5B white-knight bid for Schering on March 23, 2006. History
Operations Bayer CropScience In 2002 Bayer AG acquired Aventis CropScience and formed Bayer CropScience. The company is now one of the world's leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and plant biotechnology. In addition to conventional agrochemical business it is involved in genetic engineering of food. Bayer Leverkusen In 1904, the company founded the sports club Bayer Leverkusen, best known for its football team. Controversy Bayer AG is involved in an ongoing controversy with French and Nova Scotian beekeepers over claimed pesticide kills of honeybees from its seed treatment insecticide imidacloprid. France has since issued a provisional ban on the use of Imidacloprid for corn seed treatment pending further action. A consortium of U.S. beekeepers has also filed a civil suit against Bayer CropScience for alleged losses. Austrian journalist Klaus Werner alleged in his Black Book on Brand Companies, that the Bayer subsidiary H.C. Starck financed the civil war in the Democratic Republic of Congo by trading illegally with the mineral coltan. The allegations were also reveiwed by a U.N. panel of experts, but specific claims against Starck since 2001 could not be proven. A cite from http://www.haemophilia-litigation.com/, access date 31.05.2006: "After 1978, there were four major companies in the United States engaged in the manufacture, production and sale of Factor VIII and IX: Armour Pharmaceutical Company, Bayer Corporation and its Cutter Biological division, Baxter Healthcare Corporation and its Hyland Pharmaceutical division and Alpha Therapeutic Corporation, which have been or are defendants in certain lawsuits. The plaintiffs allege that the companies manufactured and sold blood factor products as beneficial "medicines" that were, in fact, contaminated with HIV and/or HCV and resulted in the mass infection and/or deaths of thousands of haemophiliacs worldwide. It is believed that three of these companies, Alpha, Baxter and Cutter, recruited and paid donors from high risk populations, including prisoners, intravenous drug users, and blood centers with predominantly homosexual donors, to obtain blood plasma used for the production of Factor VIII and IX. Plaintiffs allege that these companies failed to exclude donors, as mandated by federal law, with a history of viral hepatitis. Such testing could have substantially reduced the likelihood of plasma containing HIV and/ or HCV entering plasma pools." Bayer's anti-cholesterol drug, Baycol (also known as Lipobay and cerivastatin), has deadly side effects. The Food and Drug Administration received reports of 31 US deaths due to rhabdomolysis, a potentially fatal adverse muscle reaction that results in muscle cell breakdown and release of the contents of muscle cells in the bloodstream. Symptoms include muscle pain, weakness, fever, nausea, and vomiting. Bayer admitted that the drug might have killed 52 people already worldwide, with another 1,100 potentially crippled. Although Bayer voluntarily recalled the drug after a large number of deaths, Germany's health minister, on 25 August 2001, accused Bayer of sitting on research documenting Baycol's lethal side-effects for nearly two months before the government in Berlin was informed.' There have been many individual and class action law suits, including one in Pennsylvania which cited 480 cases of Baycol-related illnesses. The number of Baycol related deaths has risen to almost 100. In October 2001, Bayer was taken to court after 24 children in the remote Andean village of Tauccamarca were killed and 18 more severely poisoned when they drank a powdered milk substitute that had been contaminated with methyl parathion. The white powder that resembles powdered milk and has no strong chemical odour was packaged in small plastic bags that provide no protection to users and give no indication of the danger of the product within. The bags were labelled in Spanish only, and carried drawings of healthy carrots and potatoes but no pictograms indicating danger or toxicity. Using Baytril and other fluoroquinolenes in poultry and cattle leads to bacteria resistance bacteria and pathogens in animals, making is possible for strains of resistant bacteria to enter the human body. This makes human versions of the drug ineffective in treating people infected by these bacteria, which could be life-threatening to the elderly, to children and to those with depressed immune systems or in weakened conditiones. Fluoroquinolones are commonly prescribed to treat serious gastrointestinal illness, including from the common Campylobacter and Salmonella bacterias. Campylobacter accounts for nearly two million illnesses and 100 deaths each year, and Salmonella accounts for 1.3 million illnesses and about 500 deaths annually. Very few bacteria were found resistant to fluoroquinolones until the drugs also began to be used in poultry in 1995. By 1998, 13 percent of Campylobacter tested in humans were resistant to fluoroquinolones, and by 1999, nearly 18 percent of Campylobacter were found to be resistant. After data collected by the US Centers for Disease Control and Prevention showed that the use of fluoroquinolones in poultry was speeding up the bacteria's development of resistance to the drug, the US Food and Drug Administration concluded that the health of at least 5,000 Americans is affected each year by the use of these drugs in chickents. It also proposed to ban this use. Abbott Laboratories, one of the two producers of poultry fluoroquinolones in the US, voluntarily withdrew its product, but Bayer refused to comply with the proposed ban and instead requested a hearing on the proposal. This hearing may take years to complete, and by then the ban may be a moot point since the drug may be ineffective in humans by the time the FDA is able to issue a final ban on the use of these drugs in poultry. Many NGOs, such as the federal Centers for Disease Control and Prevention and the World Health Organization, have strongly advocated a ban for years. On 31 October 2000, Environmental Defense, the American Public Health Association, Center for Science in the Public Interest; Delmarva Poultry Justice Alliance; Food Animal Concerns Trust; Global Resources Action Center for the Environment; Institute for Agriculture and Trade Policy; National Catholic Rural Life Conference; Physicians for Social Responsibility; and Union of Concerned Scientists signed a letter to the Bayer Corporation asking it to comply voluntarily with the proposed ban. In November, more than 180 individual health care professionals and several medical organizations, including the American Medical Association and the American College of Preventive Medicine, sent a similar letter to Bayer. But Bayer has recently spent over 50 million US$ to build new production facilities for Baytril in Germany and the US. The company claimed that Baytril is completely harmless in a letter to veterinarians: "Bayer has and always will play a leading role in defending fluoroquinolones". In January 2001, Bayer agreed to pay $14 million to the United States and 45 states to settle allegations under the federal False Claims Act that the company caused physicians and other health care providers to submit fraudulently inflated reimbursement claims to the state and federally funded Medicaid program.* In September 2006, Bayer A.G. was faulted by the FDA for not revealing during testimony the existence of a commissioned retrospective study of 67,000 patients, 30,000 of whom received Trasylol and the rest other anti-fibrinolytics. The study concluded Trasylol carried greater risks. The FDA was alerted to the study by one of the researchers involved. Although the FDA issued a statement of concern they did not change their recommendation that the drug may benefit certain subpopulations of patients. In a Public Health Advisory Update dated October 3, 2006, the FDA recommended that "physicians consider limiting Trasylol use to those situations in which the clinical benefit of reduced blood loss is necessary to medical management and outweighs the potential risks" and carefully monitor patients. Trasylol Public Health Advisory Update Diversity Bayer was named one of the 100 Best Companies for Working Mothers in 2004 by Working Mothers magazine. See also | |||||||||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||||||||
 |
|
| |